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Abstract
IMPORTANCE—The increasing prevalence of pediatric chronic disease has resulted in increased 
exposure to long-term drug therapy in children. The duration of recently completed drug trials that 
support approval for drug therapy in children with chronic diseases has not been systematically 
evaluated. Such information is a vital first step in forming safety pharmacovigilance strategies for 
drugs used for long-term therapy in children.
OBJECTIVE—To characterize the duration of clinical trials submitted to the US Food and Drug 
Administration (FDA) for pediatric drug approvals, with a focus on drugs used for long-term 
therapy.
DESIGN AND SETTING—A review was performed of all safety and efficacy clinical trials 
conducted under the Best Pharmaceuticals for Children Act or the Pediatric Review Equity Act 
and submitted to the FDA from September 1, 2007, to December 31, 2014, to support the approval 
of drugs frequently used for long-term therapy in children. Statistical analysis was performed from 
July 1, 2015, to December 31, 2017.
MAIN OUTCOMES AND MEASURES—Maximum duration of trials submitted to support 
FDA approval of drugs for children.
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RESULTS—A total of 306 trials supporting 86 drugs intended for long-term use in children were 
eligible for the primary analysis. The drugs most commonly evaluated were for treatment of 
neurologic (25 [29%]), pulmonary (16 [19%]), and anti-infective (14 [16%]) indications. The 
median maximum trial duration by drug was 44 weeks (minimum, 1.1 week; maximum, 364 
weeks). For nearly two-thirds of the drugs (52 [61%]), the maximum trial duration was less than 
52 weeks. For 10 of the drugs (12%), the maximum trial duration was 3 years or more. Maximum 
duration of trials did not vary by therapeutic category, minimum age of enrollment, calendar year, 
or legislative mandate.
CONCLUSIONS AND RELEVANCE—Pediatric clinical trials designed to sufficiently 
investigate drug safety and efficacy to support FDA approval are of relatively limited duration. 
Given the potential long-term exposure of patients to these drugs, the clinical community should 
consider whether new approaches are needed to better understand the safety associated with long-
term use of these drugs.
During the past 20 years, research has established marked differences between children and 
adults in drug pharmacokinetics and pharmacodynamics. If pharmacokinetics and 
pharmacodynamics are not adequately considered in pediatric dosing, ontogenesis of drug 
receptors and pathways of biotransformation can lead to therapeutic failure or drug toxic 
effects.1–5
Through mechanisms and incentives provided in the Best Pharmaceuticals for Children Act 
(BPCA) and the Pediatric Research Equity Act (PREA), the US government recognizes the 
importance of studying drug safety and efficacy within pediatric populations.1 These 
legislative acts have had notable success, resulting thus far in more than 700 changes in US 
Food and Drug Administration (FDA) product labels to include pediatric information.6 
However, the study of drugs within pediatric populations is complex. Chronic disease is 
becoming more prevalent among children and often requires lifelong drug therapy.7–9 
Furthermore, the administration of some drugs during vulnerable periods of growth and 
development may have implications for the attainment of adequate growth and development 
among children.10–12 Given the potential for long-term administration of drugs to pediatric 
patients, drug safety may need to be assessed for prolonged durations and during vulnerable 
periods of growth and development.
We have limited understanding of the current state of long-term drug safety evaluations in 
children. To improve our understanding, we evaluated the duration of clinical trials 
submitted to the FDA under BPCA and PREA, with a focus on drugs potentially 
administered to children with chronic health conditions. We then reviewed the literature for 
other studies conducted for children or adults that could provide guidance for feasibility and 
alternative methods for gathering data on long-term drug administration in children. Such 
efforts are necessary first steps toward understanding the availability of data on long-term 
drug safety in children.
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Methods
Data Sources and Inclusion Criteria
We used the FDA’s Document Archiving, Reporting, and Regulatory Tracking System 
electronic database as our data source for clinical trial submissions to the agency. Within this 
database, we identified all drugs submitted to and reviewed by the FDA, under BPCA and 
PREA, for pediatric drug approval from September 1, 2007, to December 31, 2014. Drugs 
that did not receive FDA approval for the intended pediatric indication were excluded. We 
also excluded drugs administered topically (including administration to the skin, eye, or ear) 
unless previous evidence suggested substantial systemic absorption. We extracted 
deidentified data from prospective drug trials in humans as well as FDA medical, statistical, 
and pharmacokinetic reviews of the primary data. This research study did not require 
Research Involving Human Subjects Committee review and approval because it is exempt 
from the requirements of 45 CFR §46.101b(4).
A committee of 4 pediatricians (K.O.Z., A.W.M., J.T., and S.M.), each with clinical and 
regulatory experience, characterized the potential uses of the drugs as short-term, 
intermediate, or long-term, based on the typical or expected clinical use in pediatric 
populations. The safety and efficacy data sufficient for FDA approval of a drug for its 
intended length of use may not include data on longer-term use. The analysis described 
herein focused on the trial length for drugs potentially used for the long-term medical 
management of children, excluding trials whose primary objective was to evaluate 
bioequivalence, pharmacokinetics, or a device.
Our literature review included articles referenced in Medline and PubMed as of February 12, 
2018. Search terms were limited to “safety” AND the generic or brand name for the specific 
drug of interest OR “long-term” AND “safety” AND the generic or brand name for the 
specific drug of interest.
Definitions and Outcomes
The committee defined short-term therapy as drugs typically administered for less than 3 
months, intermediate therapy as drugs typically administered for 3 to 6 months, and long-
term therapy as drugs typically administered for longer than 6 months. Drugs classified as 
long-term therapy were further classified as continuous or intermittent. Continuous drugs 
were those administered on a scheduled basis dependent on drug pharmacokinetics (ie, daily, 
weekly, or monthly), while intermittent drugs were those administered seasonally.
We classified drugs into the following therapeutic categories according to the primary 
indication or affected organ system: anti-infectives, biologics, cardiology, dermatology, 
endocrinology and metabolism, gastroenterology, hematology, neurology, pulmonology, and 
miscellaneous. The miscellaneous category included drugs for urologic indications (eg, 
overactive bladder) and those for ophthalmologic disease without anti-infective activity. We 
designated the following age groups according to the minimum age required for enrollment 
in each trial: infants (<1 year), children (1 to <9 years), preadolescents (9 to <12 years), and 
adolescents (12 to ≤17 years).
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For our analysis, we identified all trials submitted as primary evidence for pediatric drug 
efficacy and safety. We defined trial duration as the sum of controlled and uncontrolled 
periods during which children received drug therapy. The entire duration of crossover trials 
and trials with cyclical drug administration, including interval periods of drug washout or 
time off therapy, was included. For each drug (unit of analysis), we identified the median 
maximum trial duration. We then compared the maximum trial duration with the study 
durations identified in our literature review and identified specific drugs and drug classes 
that might warrant further safety assessments based on available data.
Data Collection
We collected the following information regarding each drug trial: therapeutic area, 
indication, clinical trial design (eg, open-label uncontrolled, randomized controlled, or long-
term extension), ages studied, duration of drug receipt (weeks), year of FDA evaluation, and 
legislation under which the study took place (ie, BPCA or PREA). In our literature review, 
we extracted information regarding patient population, type and duration of evaluation, and 
any noted safety concerns or calls for additional long-term data in children.
Statistical Analysis
Statistical analysis was performed from July 1, 2015, to December 31, 2017. We used 
standard summary statistics, including counts (with percentages) and medians (25th and 
75th percentiles) to describe the study variables. We evaluated outcomes by therapeutic 
classification and age category, and made comparisons using a Wilcoxon rank sum test. 
Changes in trial duration by study year were evaluated using Kruskal-Wallis equality-of-
populations rank test. We used STATA, version 14.1 (StataCorp) to perform all statistical 
analyses. All P values were from 2-sided tests and results were deemed statistically 
significant at P < .05.
Results
We identified 201 drugs submitted for pediatric labeling during the study period. Of these, 
we excluded 33 drugs that were not approved, 19 vaccines, 3 drugs used for imaging studies, 
and 19 topical drugs. Of the remaining 127 drugs, we identified 33 that would be used for 
short-term indications, 5 for intermediate-length indications, and 86 drugs potentially used 
for long-term therapy. Pharmacokinetic trials were submitted for only 3 drugs. A total of 306 
trials supporting the 86 long-term therapy drugs were eligible for our analysis (eTable in the 
Supplement). Of the 86 drugs, 19 (22%) were characterized as long-term intermittent and 67 
(78%) as long-term continuous (Figure 1).
A total of 25 (29%) of the 86 included drugs were for neurologic indications, 16 (19%) were 
for pulmonary indications, and 14 (16%) were for anti-infective indications (Table 1). Trials 
for nearly half of the drugs (40 [47%]) were conducted in response to BPCA alone or BPCA 
and PREA, and the remainder were in response to PREA alone. For 24 of the drugs (28%), 
the minimum age of enrollment in the trials was younger than 1 year. A total of 42 drugs 
(49%) had trials that initiated enrollment at ages 1 to 8 years, 7 (8%) initiated enrollment at 
ages 9 to 11 years, and 10 (12%) initiated enrollment at ages 12 to 17 years.
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The median (25th and 75th percentiles) maximum trial duration by drug was 44 weeks (12 
weeks and 53 weeks). For nearly two-thirds of the drugs (52 [61%]), the duration was less 
than 52 weeks (<1 year) (Table 2). The longest trial duration by drug (364 weeks/7 years) 
investigated the safety and efficacy of a phenyalanine hydroxylase activator for children with 
phenylketonuria, while the shortest duration (1.1 week) investigated the efficacy and safety 
of montelukast for the indication of exercise-induced asthma (longer studies were done for 
the other pediatric indications for montelukast).
Although trial duration appeared different between therapeutic categories, the overall 
distributions of trial durations were statistically similar because of the wide variability in the 
trial lengths. For example, the median (25th and 75th percentiles) maximum duration for 
biologic drug trials was 132 weeks (52 weeks and 260 weeks); for cardiovascular drugs, 
median maximum duration was 54 weeks (53 weeks and 57 weeks; P = .44) (Figure 2). 
Similarly, trial duration did not vary according to classification as a long-term intermittent or 
long-term continuous drug, with median (25th and 75th percentiles) maximum durations of 
12 weeks (8 weeks and 52 weeks) for long-term intermittent drugs and 48 weeks (15 weeks 
and 58 weeks) for long-term continuous drugs (P = .08).
Overall distribution of trial duration varied inconsistently by indication within a therapeutic 
category. For example, within the neurology category, drugs with a primary indication for 
seizures had a median (25th and 75th percentiles) maximum trial duration (139.5 weeks 
[242 weeks and 291 weeks]) that was statistically significantly different from those with a 
nonseizure indication (29 weeks [8 weeks and 48 weeks]; P = .04). However, within the 
pulmonary category, drugs with a primary asthma indication had a similar median (25th and 
75th percentiles) maximum trial duration (34 weeks [8 weeks and 52 weeks]) compared with 
those without such an indication (25 weeks [14 weeks and 52 weeks]; P = .91). The FDA 
labels for drugs denoted as long-term continuous were each labeled for “maintenance 
therapy” or “for treatment of” a specified chronic condition. Labels for long-term 
intermittent drugs most often had specified durations of short-term use consistent with 
durations of clinical trials submitted to support labeling for the specified drug.
Trials enrolling participants of minimum ages of 0 (infant), 1 (child), or 12 (adolescent) 
years all had similar median (25th and 75th percentiles) maximum durations (infant, 42 
weeks [10 weeks and 59 weeks]; child, 50 weeks [16 weeks and 54 weeks]; and adolescent, 
52 weeks [12 weeks and 53 weeks) (Figure 3). Median (25th and 75th percentiles) 
maximum trial duration did not vary according to whether the trial was mandated by BPCA 
and PREA (48 weeks [15 weeks and 100 weeks]) or PREA alone (29 weeks [10.7 weeks and 
52 weeks]) (P = .17). Furthermore, trial duration did not change significantly over time: in 
2007, the median (25th and 75th percentiles) maximum duration was 52 weeks (12 weeks 
and 54 weeks); in 2014, this duration was 39 weeks (25 weeks and 86 weeks) (P = .70). 
Approximately 35% of included drugs (30) had extension trials, most commonly occurring 
for neurologic drugs (14 of 25 [56%]). Only 3 of the 30 drugs (10%) with extension trials 
used a controlled study design.
According to our review of the literature, long-term evaluations exceeded the duration of 
trials submitted as primary evidence to the FDA for 69 (80%) of the 86 drugs. For 67 drugs 
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(78%),long-term evaluations included prospective studies, most often characterized as 
nonrandomized, open-label, observational studies with standardized follow-up evaluation. 
Children were included in evaluations for 37 (43%) of the drugs.
Several safety findings with potential long-term implications emerged from our literature 
review. First, although most studies did not identify substantial effects of inhaled cortico 
steroids on linear growth or the hypothalamic-pituitary-axis, investigators and clinicians 
remain concerned about this potential phenomenon and highlight a need for more prolonged 
evaluations, particularly at critical times of pediatric growth and development.13–18 Second, 
proton pump inhibitors have been associated with gastric hyperplasia among those with 
long-term use, and existing evaluations in children are considered inadequate to rule out this 
adverse event.19–21 Third, short-term and longer-term evaluations of stimulants have been 
associated with insomnia, concern for abnormal cognitive development, and impaired 
growth; quantification of risks are not fully elucidated.22–24 Mood stabilizers and anti-
psychotics have shown associations with weight gain and metabolic derangements, the long-
term effects of which are unclear.25–27Omalixumab carries an FDA warning because heart 
and brain issues have not been ruled out with existing studies.28 Finally, tenofovir may have 
implications for long-term renal function.29–32 We did not identify substantial long-term 
safety concerns for other evaluated drugs or drug classes.
Discussion
In our analysis of data submitted to the FDA from 2007 to 2014 to support pediatric 
indications for drugs that are commonly used for chronic conditions, we found that the 
median maximum trial duration by drug infrequently exceeded 1 year. Furthermore, trial 
duration did not notably vary with therapeutic category, minimum age of enrollment, 
calendar year, or legislative mandate. Review of the literature suggests that longer-term data 
in nonrandomized, observational studies are available for many drugs and may provide 
potentially important information regarding safety signals.
Admittedly, our study is limited given its purely descriptive nature. We have categorized our 
data to facilitate analysis, but recognize that the available data are heterogeneous with 
respect to the drugs evaluated, indications for therapy, study populations, and disease 
processes. Such categorization does not allow for evaluation of more subtle differences 
between trials. Finally, we have characterized drugs as long-term intermittent or long-term 
continuous based on clinical experience and prior documentation of long-term use of drugs 
even in cases for which the labeled indication may not support such use (eg, proton pump 
inhibitors).33 We therefore acknowledge that this classification introduces some bias in our 
analysis. Nonetheless, our study provides important baseline information that can inform 
discussion regarding long-term drug safety data in children.
Our findings suggest that these pediatric studies may not provide complete safety data across 
all critical periods of growth and development. This observation may be important because 
multiple periods of critical pediatric growth and development exist, including marked 
deceleration in linear growth and weight gain during the first 2 years of life, and initiation of 
puberty around ages 11 to 13 years, accompanied by acceleration in linear growth that may 
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last for 3 to 4 years.34,35 Although the first 3 years of life are often considered more critical 
than older ages for brain development, biochemical studies of brain metabolism suggest that 
high brain metabolic rates characteristic of early childhood may not decline to adult levels 
until ages 16 to 18 years, suggesting that the school-age and adolescent periods are equally 
critical periods of brain development.36 Given this information, even the longest trial 
duration identified in our study (364 weeks/7 years) does not completely evaluate potential 
critical stages of all pediatric growth and development periods, nor does it begin to 
characterize the exposure associated with lifelong therapy.1
Administration of dexamethasone to premature infants provides a pertinent example in 
which long-term follow-up after limited administration in the neonatal period revealed 
important information regarding drug safety associated with exposure during critical periods 
of cognitive development. Extensive investigation dating to 1990 identified dexamethasone 
as an effective therapy for facilitation of extubation and prevention of bronchopulmonary 
dysplasia in premature infants.37 However, in long-term follow-up studies,38 investigators 
identified a statistically significantly increased risk of cerebral palsy among infants who 
received dexamethasone, compared with those who did not, with a number needed to harm 
of 4. Examples such as this one underscore potential issues with limited long-term data on 
drug safety in children.
On average, more than 1 decade elapses between initial laboratory formulation of a drug to 
readiness for public use in adults.39 Public availability of data on drug efficacy and safety in 
children may require an additional 6 years.40 Requiring that studies be designed to cover all 
the potential periods of critical development would make pediatric drug development 
infeasible. Furthermore, although investigators have traditionally touted the controlled 
clinical trial as the most rigorous source of data, multiple barriers to the conduct of clinical 
trials exist and may be exacerbated when clinical trials are of prolonged duration.41,42 A 
recent investigation of more than 500 clinical trials conducted for children found that nearly 
20% were discontinued early, largely owing to poor patient accrural.43 Previous investigators 
have long documented attrition rates as high as 15% in longitudinal pediatric studies and up 
to 44% in some interventional studies in specific pediatric populations.44–46 Furthermore, 
the relatively small sample sizes of pediatric trials compared with adult trials, combined with 
the lack of a control group in many extension trials, may raise concern about the level of 
evidence for safety such trials can provide.47,48 Innovative approaches to acquire 
information on long-term drug safety in children are needed that continue to make important 
therapeutics available to children in a timely manner.
Multiple approaches are likely needed to obtain high-quality, long-term safety data for drugs 
used to treat chronic pediatric conditions. Currently, the FDA evaluates need for long-term 
safety assessment based on any safety concerns related to the specific effects of the drugs, 
the intended duration of treatment, and potential exposure during critical periods of growth 
and development, despite lack of conclusive evidence that all drugs used long-term in 
children will have specific effects on growth and development. In addition, the Food and 
Drug Administration Amendments Act of 2007 required increased activities for active post 
marketing risk identification and analysis. More importantly, it may be possible to leverage 
safety information from other populations, including adults and other pediatric age groups.
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Our review of the literature suggests that long-term data can take many forms, ranging from 
open-label extension trials49–51 after randomized studies, to registries52 that capture data for 
specific disease processes, or prospective longitudinal studies53 designed to answer specific 
scientific questions. Furthermore, with increasing administration of drugs for chronic 
conditions such as attention-deficit/hyperactivity disorder and asthma, we have a ready 
source of real-world data from which to potentially evaluate longer-term safety.54
Although we were able to identify potentially important safety signals from different data 
sources in the literature, each source has benefits and limitations, and our search may have 
introduced bias due to the nature of our study question. In general, ability to use the data in a 
meaningful way hinges on collecting quality data from an adequate pediatric population. To 
this end, the following approaches may enhance data quality: 1) use of existing literature to 
highlight areas for more urgent evaluation and lessons learned about specific data sources 
for specific drugs/drug classes; 2) collaboration between stake-holders and formation of 
networks for large sample sizes and acquisition of protocol-directed data collection in 
prospective observational studies for specific safety signals; 3) investigation of methods to 
decrease attrition and improve data collection in extension phases of clinical trials or other 
prospective evaluations; and 4) application of rigorous pharmacoepidemiologic analysis 
methods to existing data sources (‘real-world data’) and naturally occurring cohorts (eg, 
clinical cohorts, members of disease registries). Concerted efforts among all stakeholders 
will enable us to continue to advance pediatric drug development with regard to long-term 
pediatric drug safety while maintaining efficient and timely access to approved therapies for 
all children.
Limitations
This study has some limitations. As mentioned above, our study is limited by its purely 
descriptive nature; the available data are heterogeneous with respect to the drugs evaluated, 
indications for therapy, study populations, and disease processes, which did not allow us to 
evaluate more subtle differences between trials. Also, our classification (long-term 
intermittent vs continuous) is based on experience, which may have introduced bias into our 
analyses.
Conclusions
Pediatric clinical trials that are designed to sufficiently investigate drug safety and efficacy to 
support FDA approval are of relatively limited duration. Given the potential long-term 
exposure of patients to these drugs, the clinical community should consider whether new 
approaches are needed to better understand the safety of long-term use of these drugs.
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Key Points
Question
What are the durations of pediatric clinical trials recently submitted to the US Food and 
Drug Administration, and how can this knowledge inform discussions of safety 
pharmacovigilance follow-up for drugs that might be used for long-term therapy in the 
pediatric population?
Findings
This study found that nearly two-thirds of pediatric clinical trials submitted to support the 
approval of drugs with potential long-term use in the pediatric population are shorter than 
52 weeks.
Meaning
Pediatric clinical trials that are sufficient to support US Food and Drug Administration 
drug approval may require additional strategies to ensure data availability for 
understanding long-term drug safety in children.
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Figure 1. 
CONSORT Diagram
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Figure 2. Maximum Trial Duration by Therapeutic Category
The black lines represent the median duration per therapeutic category. Upper and lower 
bounds of the box represent the 75th (quartile 3 [Q3]) and 25th (quartile 1 [Q1]) percentiles, 
respectively. The whiskers represent the following values:Q3 + 1.5(Q3 − Q1) andQ1 
− 1.5(Q3 − Q1). Outliers within each therapeutic category are denoted by circles.
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Figure 3. Maximum Trial Duration by Age Category
The black lines represent the median duration per age group. Upper and lower bounds of the 
box represent the 75th (quartile 3 [Q3]) and 25th (quartile 1 [Q1]) percentiles, respectively. 
The whiskers represent the following values:Q3 + 1.5(Q3 − Q1) and Q1 − 1.5(Q3 − Q1). 
Outliers within age group category are denoted by circles.
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Table 1.
Drugs Used for Long-term Therapy and Supporting Trials by Therapeutic Category
Category
Drugs, No. (%)
Trials, No. (%) (N = 306)Overall (N = 86) With Extension Trials (n = 30)
Neurology 25 (29) 14 (47) 109 (35.6)
Pulmonary 16 (19) 3 (10) 91 (29.7)
Infectious diseases 14 (16) 3 (10) 35 (11.4)
Gastrointestinal 10 (12) 0 26 (8.5)
Biologic 6(7) 4(13) 20 (6.5)
Cardiology 5 (6) 5(17) 8 (2.6)
Hematology 5 (6) 0 6 (2.0)
Endocrine 4(5) 1(3) 6 (2.0)
Miscellaneous 1 (1) 0 5 (1.6)
Dermatology 0 0 0
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Table 2.
Percentage of Drugs by Maximum Trial Duration for Long-term Therapeutics
Maximum Trial Duration, Median, wk
Drugs, No. (%)
Total (N = 86) Long-term Intermittent (n = 19) Long-term Continuous (n = 67)
<52 52 (61) 13 (68) 39 (58)
≥52 to <104 21 (24) 5(26) 16 (24)
≥104 to<156 3(4) 0 3(5)
≥156 to <208 2(2) 0 2 (3)
≥208 to <260 2 (2) 0 2 (3)
≥260 6 (7) 1(5) 5 (8)
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